Dr Sally Price

Sally is a Senior Director of Translational Medicine at Evox therapeutics, an Oxford based Biotech developing engineered exosomes as therapeutics for rare metabolic diseases. She leads a team of scientists taking potential drugs from proof of concept to clinical testing across Evox’s portfolio, including exosomes delivering AAV, siRNA and genetic medicines. Prior to joining Evox, Sally was Head of Cell and Translational Science at Medicines Discovery Catapult, supporting UK drug discovery companies develop new medicines through technology innovation and collaboration. She led teams undertaking preclinical imaging, biomarker discovery and strategy development and developing human relevant complex cell models; all aimed at improving translational success of potential new drugs. Sally is an experienced toxicologist having spent 10 years in preclinical safety at AstraZeneca, leading the Investigative Pathology team and gaining American Board Certification in Toxicology. During her time at BioCity, she trained in business model generation and has worked with investment managers to identify and support promising new biotechs. Sally has a degree in Pharmacology from the University of Leeds and a PhD in Neuroscience from the University of Manchester. She enjoys working in collaborative projects and was awarded a Movers and Shakers in BioBusiness Award for her collaborative work in establishing one of the UK Government Lighthouse Network Labs in response to the covid-19 pandemic. Sally is passionate about improving translational success through the use of humanised preclinical models, novel technologies and human data.